{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T17:28:37Z","timestamp":1795195717387,"version":"4.10.3"},"reference-count":156,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T00:00:00Z","timestamp":1702684800000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1053\/j.gastro.2022.10.008","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T06:52:11Z","timestamp":1665557531000},"page":"42-60.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["Current Best Practice in Hepatitis B Management and Understanding Long-term Prospects for Cure"],"prefix":"10.1053","volume":"164","author":[{"given":"David","family":"Yardeni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyong-Mi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2837-0188","authenticated-orcid":false,"given":"Marc G.","family":"Ghany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6564","key":"10.1053\/j.gastro.2022.10.008_bib1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1126\/science.abi5658","article-title":"Ten millennia of hepatitis B virus evolution","volume":"374","author":"Kocher","year":"2021","journal-title":"Science"},{"key":"10.1053\/j.gastro.2022.10.008_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.653684","article-title":"Origins and evolution of the primate hepatitis B virus","volume":"12","author":"Locarnini","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1053\/j.gastro.2022.10.008_bib3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10003","key":"10.1053\/j.gastro.2022.10.008_bib4","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2022.10.008_bib5","unstructured":"World Health Organization. Hepatitis B key facts. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b. Accessed January 21, 2022."},{"key":"10.1053\/j.gastro.2022.10.008_bib6","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1001\/jama.284.23.3040","article-title":"Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls","volume":"284","author":"Chang","year":"2000","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2022.10.008_bib7","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1053\/j.gastro.2016.05.048","article-title":"Long-term effects of hepatitis B immunization of infants in preventing liver cancer","volume":"151","author":"Chang","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.10.008_bib8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-020-0332-6","article-title":"Progress towards elimination goals for viral hepatitis","volume":"17","author":"Cox","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.10.008_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104925","article-title":"Hepatitis B virus biology and life cycle","volume":"182","author":"Tsukuda","year":"2020","journal-title":"Antiviral Res"},{"issue":"3","key":"10.1053\/j.gastro.2022.10.008_bib11","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3390\/v13030368","article-title":"HBV-integration studies in the clinic: role in the natural history of infection","volume":"13","author":"Pollicino","year":"2021","journal-title":"Viruses"},{"issue":"409","key":"10.1053\/j.gastro.2022.10.008_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0241","article-title":"RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg","volume":"9","author":"Wooddell","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.gastro.2022.10.008_bib13","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1073\/pnas.0401771101","article-title":"Genomic analysis of the host response to hepatitis B virus infection","volume":"101","author":"Wieland","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2022.10.008_bib14","doi-asserted-by":"crossref","first-page":"9369","DOI":"10.1128\/JVI.79.15.9369-9380.2005","article-title":"Stealth and cunning: hepatitis B and hepatitis C viruses","volume":"79","author":"Wieland","year":"2005","journal-title":"J\u00a0Virol"},{"key":"10.1053\/j.gastro.2022.10.008_bib15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.antiviral.2015.07.006","article-title":"Treatment of chronic hepatitis B with pattern recognition receptor agonists: current status and potential for a cure","volume":"121","author":"Chang","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1053\/j.gastro.2022.10.008_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.immuni.2014.12.016","article-title":"The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus","volume":"42","author":"Sato","year":"2015","journal-title":"Immunity"},{"key":"10.1053\/j.gastro.2022.10.008_bib17","doi-asserted-by":"crossref","first-page":"12193","DOI":"10.1073\/pnas.1412631111","article-title":"Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems","volume":"111","author":"Shlomai","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2022.10.008_bib18","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/gut.2008.163600","article-title":"Early kinetics of innate and adaptive immune responses during hepatitis B virus infection","volume":"58","author":"Fisicaro","year":"2009","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2022.10.008_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.pathol.1.110304.100230","article-title":"Immunobiology and pathogenesis of viral hepatitis","volume":"1","author":"Guidotti","year":"2006","journal-title":"Annu Rev Pathol"},{"key":"10.1053\/j.gastro.2022.10.008_bib20","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/nm1096-1104","article-title":"The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response","volume":"2","author":"Rehermann","year":"1996","journal-title":"Nat Med"},{"key":"10.1053\/j.gastro.2022.10.008_bib21","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/jvh.12305","article-title":"Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases","volume":"22","author":"Hwang","year":"2015","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2022.10.008_bib22","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/hep.27609","article-title":"Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?","volume":"61","author":"Di Bisceglie","year":"2015","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.10.008_bib23","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1053\/jhep.2003.50453","article-title":"Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection","volume":"38","author":"Milich","year":"2003","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.10.008_bib24","doi-asserted-by":"crossref","first-page":"9652","DOI":"10.1128\/JVI.00867-09","article-title":"The size of the viral inoculum contributes to the outcome of hepatitis B virus infection","volume":"83","author":"Asabe","year":"2009","journal-title":"J\u00a0Virol"},{"key":"10.1053\/j.gastro.2022.10.008_bib25","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.jhep.2016.10.002","article-title":"T\u00a0cell regulation in HBV-related chronic liver disease","volume":"66","author":"Ferrari","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.10.008_bib26","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1053\/j.gastro.2015.11.050","article-title":"Hepatitis B virus-specific and global T-cell dysfunction in chronic hepatitis B","volume":"150","author":"Park","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.10.008_bib27","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1172\/JCI121957","article-title":"PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection","volume":"128","author":"Salimzadeh","year":"2018","journal-title":"J\u00a0Clin Invest"},{"key":"10.1053\/j.gastro.2022.10.008_bib28","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1172\/JCI121960","article-title":"Circulating and intrahepatic antiviral B cells are defective in hepatitis B","volume":"128","author":"Burton","year":"2018","journal-title":"J\u00a0Clin Invest"},{"key":"10.1053\/j.gastro.2022.10.008_bib29","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jhep.2014.07.005","article-title":"Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation","volume":"61","author":"Bengsch","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1053\/j.gastro.2022.10.008_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007715","article-title":"Distinct phenotype and function of circulating Vdelta1+ and Vdelta2+ gammadeltaT-cells in acute and chronic hepatitis B","volume":"15","author":"Chang","year":"2019","journal-title":"PLoS Pathog"},{"key":"10.1053\/j.gastro.2022.10.008_bib31","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3389\/fimmu.2020.00849","article-title":"Pathogenetic mechanisms of T cell dysfunction in chronic HBV infection and related therapeutic approaches","volume":"11","author":"Fisicaro","year":"2020","journal-title":"Front Immunol"},{"key":"10.1053\/j.gastro.2022.10.008_bib32","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1172\/JCI33402","article-title":"Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection","volume":"118","author":"Lopes","year":"2008","journal-title":"J\u00a0Clin Invest"},{"issue":"7","key":"10.1053\/j.gastro.2022.10.008_bib33","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.146883","article-title":"Highly multiplexed 2-dimensional imaging mass cytometry analysis of HBV-infected liver","volume":"6","author":"Traum","year":"2021","journal-title":"JCI Insight"},{"key":"10.1053\/j.gastro.2022.10.008_bib34","unstructured":"Centers for Disease Control and Prevention. Hepatitis B vaccination: information for healthcare providers. Available at: https:\/\/www.cdc.gov\/vaccines\/vpd\/hepb\/hcp\/index.html. Accessed February 18, 2022."},{"key":"10.1053\/j.gastro.2022.10.008_bib35","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2017.05.008","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"67","author":"Lok","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.10.008_bib36","doi-asserted-by":"crossref","unstructured":"Cornberg M, Lok AS, Terrault NA, et\u00a0al. Guidance for design and endpoints of clinical trials in chronic hepatitis B - report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference [published online ahead of print November 12, 2019]. Hepatology https:\/\/doi.org\/10.1002\/hep.31030.","DOI":"10.1002\/hep.31030"},{"key":"10.1053\/j.gastro.2022.10.008_bib37","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","article-title":"Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis","volume":"156","author":"Yeo","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.10.008_bib38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S2468-1253(18)30308-X","article-title":"Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses","volume":"4","author":"Zhou","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.10.008_bib39","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.10.008_bib40","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.10.008_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1053\/j.gastro.2022.10.008_bib42","series-title":"World Health Organization. Guidelines for the Prevention, Care and Treatment of Persons With Chronic Hepatitis B Infection","year":"2015"},{"key":"10.1053\/j.gastro.2022.10.008_bib43","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1053\/j.gastro.2017.03.016","article-title":"American Gastroenterological Association Institute technical review on the role of elastography in chronic liver diseases","volume":"152","author":"Singh","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.10.008_bib44","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/hep.29179","article-title":"Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: an individual patient data-based meta-analysis","volume":"67","author":"Herrmann","year":"2018","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.10.008_bib45","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2022.10.008_bib46","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2011.06.036","article-title":"Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma","volume":"141","author":"Chen","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.10.008_bib47","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.10.008_bib48","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/gutjnl-2017-314904","article-title":"High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B","volume":"67","author":"Kim","year":"2018","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2022.10.008_bib49","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjmed.2003.12.040","article-title":"Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels","volume":"116","author":"Chu","year":"2004","journal-title":"Am J Med"},{"key":"10.1053\/j.gastro.2022.10.008_bib50","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/hep.21724","article-title":"Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase","volume":"46","author":"Hui","year":"2007","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.10.008_bib51","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/jvh.13185","article-title":"The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria","volume":"26","author":"Sinn","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2022.10.008_bib52","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/apt.15311","article-title":"High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation","volume":"50","author":"Choi","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.10.008_bib53","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S1473-3099(20)30692-7","article-title":"Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial","volume":"21","author":"Hsu","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1053\/j.gastro.2022.10.008_bib54","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","article-title":"Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b","volume":"135","author":"Buster","year":"2008","journal-title":"Gastroenterology"},{"issue":"9454","key":"10.1053\/j.gastro.2022.10.008_bib55","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2022.10.008_bib56","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cld.2016.06.002","article-title":"Interferon treatment for hepatitis B","volume":"20","author":"Konerman","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1053\/j.gastro.2022.10.008_bib57","first-page":"737","article-title":"[Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study]","volume":"20","author":"Zhu","year":"2012","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"10.1053\/j.gastro.2022.10.008_bib58","first-page":"446","article-title":"Extended treatment with peginterferon \u03b1-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion","volume":"14","author":"Cao","year":"2013","journal-title":"J\u00a0Dig Dis"},{"key":"10.1053\/j.gastro.2022.10.008_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2014.04.005","article-title":"Nucleoside\/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance","volume":"8","author":"Menendez-Arias","year":"2014","journal-title":"Curr Opin Virol"},{"key":"10.1053\/j.gastro.2022.10.008_bib60","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2021.12.286","article-title":"Inhibition of viral replication reduces transcriptionally active distinct hepatitis B virus integrations with implications on host gene dysregulation","volume":"162","author":"Hsu","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.10.008_bib61","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s12072-021-10235-1","article-title":"Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load","volume":"15","author":"Li","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1053\/j.gastro.2022.10.008_bib62","doi-asserted-by":"crossref","first-page":"e3324","DOI":"10.1093\/cid\/ciaa1939","article-title":"Tenofovir alafenamide to prevent perinatal hepatitis B transmission: a multicenter, prospective, observational study","volume":"7","author":"Zeng","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2022.10.008_bib63","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/apt.16043","article-title":"Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study","volume":"52","author":"Ding","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.10.008_bib64","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.10.008_bib65","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2022.10.008_bib66","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2022.10.008_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104992","article-title":"Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B","volume":"185","author":"Tout","year":"2021","journal-title":"Antiviral Res"},{"key":"10.1053\/j.gastro.2022.10.008_bib68","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.10.008_bib69","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/j.gastro.2018.11.037","article-title":"New and old biomarkers for diagnosis and management of chronic hepatitis B virus infection","volume":"156","author":"Coffin","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.10.008_bib70","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2016.04.013","article-title":"First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B","volume":"65","author":"Blank","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.10.008_bib71","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s40265-020-01400-1","article-title":"Bulevirtide: first approval","volume":"80","author":"Kang","year":"2020","journal-title":"Drugs"},{"key":"10.1053\/j.gastro.2022.10.008_bib72","unstructured":"National Institutes of Health, US National Library of Medicine. A Phase 1b\/2a Randomized, Open-label Clinical Trial of Daily Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02881008. Accessed January 21, 2022."},{"key":"10.1053\/j.gastro.2022.10.008_bib73","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coviro.2018.04.004","article-title":"Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections","volume":"30","author":"Tu","year":"2018","journal-title":"Curr Opin Virol"},{"key":"10.1053\/j.gastro.2022.10.008_bib74","first-page":"514A","article-title":"Rapid HBsAg reduction in chronic hepatitis B virus infection: preliminary results from a phase 1 study evaluating a single dose of VIR-3434, a novel neutralizing, vaccinal monoclonal antibody","volume":"74","author":"Agarwal","year":"2021","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.10.008_bib75","first-page":"LO9","article-title":"HBV RNAi inhibitor RG6346 in phase 1b-2a trial was safe, well-tolerated, and resulted in substantial and durable reductions in serum HBsAg levels","volume":"72","author":"Yuen","year":"2020","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.10.008_bib76","first-page":"S287","article-title":"Safety and antiviral activity of VIR-2218, an X-targeting RNAi therapeutic, in participants with chronic hepatitis B infection: week 48 follow-up results","volume":"75","author":"Gane","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.10.008_bib77","first-page":"S289","article-title":"Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors","volume":"75","author":"Gane","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.10.008_bib78","first-page":"62A","article-title":"Safety and pharmacodynamics of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B infection","volume":"72","author":"Yuen","year":"2020","journal-title":"Hepatology"},{"issue":"2","key":"10.1053\/j.gastro.2022.10.008_bib79","article-title":"Inhibition of HBsAg in patients with CHB by RNA interference therapeutic AB-729 is accompanied by upregulation of HBVspecific T cell activation markers","volume":"75","author":"Paratala","year":"2021","journal-title":"J\u00a0Hepatology"},{"key":"10.1053\/j.gastro.2022.10.008_bib80","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/s41591-021-01513-4","article-title":"Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial","volume":"27","author":"Yuen","year":"2021","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2022.10.008_bib81","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0168-8278(22)00444-5","article-title":"Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection on stable nucleos (t)ide analogue therapy: interim results from the randomised phase 2b B-Clear study","volume":"77","author":"Yuen","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.10.008_bib82","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1053\/j.gastro.2018.12.023","article-title":"Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection","volume":"156","author":"Yuen","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.10.008_bib83","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S2468-1253(19)30346-2","article-title":"Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial","volume":"5","author":"Yuen","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.10.008_bib84","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.gastro.2020.04.036","article-title":"JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection","volume":"159","author":"Zoulim","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.10.008_bib85","article-title":"Analysis of the longer-term safety profile of the hepatitis B virus core inhibitor ABI-H0731 in an open-label extension study","volume":"72","author":"Jacobson","year":"2020","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.10.008_bib86","first-page":"74","article-title":"Safety, pharmacokinetics (PK), and antiviral activity of the capsid assembly modulator (CAM) ALG-000184 in subjects with chronic hepatitis B (CHB)","author":"Gane","year":"2021","journal-title":"Heptology"},{"key":"10.1053\/j.gastro.2022.10.008_bib87","article-title":"EDP-514, a novel pangenotypic class II hepatitis B virus core inhibitor demonstrates significant HBV DNA and HBV RNA reductions in a phase 1b study in viremic, chronic hepatitis B infected patients","volume":"74","author":"Yuen","year":"2021","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.10.008_bib88","first-page":"504A","article-title":"EDP-514, a novel pangenotypic class II hepatitis B virus core inhibitor: preliminary results of a 28-day phase 1b study in NUC-suppressed CHB patients","volume":"74","author":"Feld","year":"2021","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.10.008_bib89","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S2468-1253(21)00176-X","article-title":"Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial","volume":"6","author":"Yuen","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.10.008_bib90","article-title":"Arbitus Biopharma. Preliminary Data Shows that Arbutus\u2019 Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity","year":"2021","journal-title":"Published December 1,"},{"key":"10.1053\/j.gastro.2022.10.008_bib91","first-page":"65A","article-title":"HBV pgRNA and DNA both rebound immediately following discontinuation of the core inhibitor vebicorvir despite continued NRTI treatment in patients with HBeAg positive chronic hepatitis B virus infection: findings from a phase 2 open label study","volume":"74","author":"Yuen","year":"2021","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.10.008_bib92","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/liv.14155","article-title":"Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection","volume":"39","author":"Marcellin","year":"2019","journal-title":"Liver Int"},{"issue":"9","key":"10.1053\/j.gastro.2022.10.008_bib93","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00836-20","article-title":"ATI-2173, a novel liver-targeted non-chain-terminating nucleotide for hepatitis B virus cure regimens","volume":"64","author":"Squires","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1053\/j.gastro.2022.10.008_bib94","first-page":"S743","article-title":"alPhase 1 Results for ATI- 2173, a novel active site polymerase inhibitor nucleotide (ASPIN), in HBV-infected subjects","volume":"75","author":"Mayers","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.10.008_bib95","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1093\/cid\/ciab763","article-title":"Pradefovir treatment in patients with chronic hepatitis B: week 24 results from a multicenter, double-blind, randomized, noninferiority, phase 2 trial","volume":"74","author":"Gao","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2022.10.008_bib96","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/apt.16196","article-title":"Randomised clinical trial: safety, efficacy and pharmacokinetics of HS-10234 versus tenofovir for the treatment of chronic hepatitis B infection","volume":"53","author":"Zhang","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.10.008_bib97","first-page":"519A","article-title":"Single-dose pharmacokinetics and safety of NCO-48 fumarate, a novel liver-targeted prodrug (LTP) of tenofovir (TFV)","volume":"74","author":"Zhi","year":"2021","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.10.008_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104815","article-title":"HBV replication inhibitors","volume":"179","author":"Pierra Rouviere","year":"2020","journal-title":"Antiviral Res"},{"issue":"6","key":"10.1053\/j.gastro.2022.10.008_bib99","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156667","article-title":"Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection","volume":"11","author":"Al-Mahtab","year":"2016","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2022.10.008_bib100","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.antiviral.2016.07.004","article-title":"Nucleic acid polymers: Broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection","volume":"133","author":"Vaillant","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1053\/j.gastro.2022.10.008_bib101","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection na\u00efve to nucleos(t)ide therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.10.008_bib102","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.omtn.2021.12.013","article-title":"Mechanism of action of hepatitis B virus S antigen transport-inhibiting oligonucleotide polymer, STOPS, molecules","volume":"27","author":"Kao","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1053\/j.gastro.2022.10.008_bib103","series-title":"Aligos Therapeutics. Aligos Halting Further Development of STOPS\u2122 Drug Candidate, ALG-010133","year":"2022"},{"key":"10.1053\/j.gastro.2022.10.008_bib104","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s00018-019-03021-8","article-title":"Orthologous CRISPR\/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus","volume":"76","author":"Kostyushev","year":"2019","journal-title":"Cell Mol Life Sci"},{"issue":"42","key":"10.1053\/j.gastro.2022.10.008_bib105","doi-asserted-by":"crossref","first-page":"E5715","DOI":"10.1073\/pnas.1518090112","article-title":"Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation","volume":"112","author":"Tropberger","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2022.10.008_bib106","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1053\/j.gastro.2022.10.008_bib107","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1128\/jvi.76.5.2579-2584.2002","article-title":"Enhancement of hepatitis B virus replication by its X protein in transgenic mice","volume":"76","author":"Xu","year":"2002","journal-title":"J\u00a0Virol"},{"issue":"7594","key":"10.1053\/j.gastro.2022.10.008_bib108","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature17170","article-title":"Hepatitis B virus X protein identifies the Smc5\/6 complex as a host restriction factor","volume":"531","author":"Decorsi\u00e8re","year":"2016","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2022.10.008_bib109","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jhep.2020.09.019","article-title":"Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx","volume":"74","author":"Cheng","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.10.008_bib110","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/hep.30491","article-title":"Pevonedistat, a neuronal precursor cell-expressed developmentally down-regulated protein 8-activating enzyme inhibitor, is a potent inhibitor of hepatitis B virus","volume":"69","author":"Sekiba","year":"2019","journal-title":"Hepatology"},{"issue":"6176","key":"10.1053\/j.gastro.2022.10.008_bib111","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"issue":"Suppl","key":"10.1053\/j.gastro.2022.10.008_bib112","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.jhep.2016.01.028","article-title":"The role of innate immunity in the immunopathology and treatment of HBV infection","volume":"64","author":"Maini","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.10.008_bib113","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.antiviral.2015.11.001","article-title":"Combination therapy including CpG oligodeoxynucleotides and entecavir induces early viral response and enhanced inhibition of viral replication in a woodchuck model of chronic hepadnaviral infection","volume":"125","author":"Meng","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1053\/j.gastro.2022.10.008_bib114","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees","volume":"144","author":"Lanford","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.10.008_bib115","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2014.12.026","article-title":"Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the woodchuck model of chronic hepatitis B","volume":"62","author":"Menne","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.10.008_bib116","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2015.02.037","article-title":"The oral Toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection","volume":"63","author":"Gane","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.10.008_bib117","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2017.10.027","article-title":"Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B","volume":"68","author":"Janssen","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.10.008_bib118","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/jvh.12942","article-title":"Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment","volume":"25","author":"Agarwal","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2022.10.008_bib119","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.31255","article-title":"Toll-like receptor 8 agonist GS-9688 induces sustained efficacy in the woodchuck model of chronic hepatitis B","volume":"73","author":"Daffis","year":"2021","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.10.008_bib120","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/S0168-8278(20)30650-4","article-title":"Efficacy and safety of 24 weeks treatment with oral TLR8 agonist selgantolimod (GS-9688, SLGN) in virally suppressed adult patients with chronic hepatitis B: a phase 2 study","volume":"73","author":"Gane","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.10.008_bib121","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S0618-8278(19)30084-2","article-title":"Ascending dose cohort study of inarigivir-A novel RIG I agonist in chronic HBV patients: Final results of the ACHIEVE trial","volume":"70","author":"Yuen","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.10.008_bib122","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/febs.13563","article-title":"The cyclic GMP-AMP synthetase-STING signaling pathway is required for both the innate immune response against HBV and the suppression of HBV assembly","volume":"283","author":"Dansako","year":"2016","journal-title":"FEBS J"},{"key":"10.1053\/j.gastro.2022.10.008_bib123","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1099\/jgv.0.000647","article-title":"Inhibition of hepatitis B virus replication by activation of the cGAS-STING pathway","volume":"97","author":"He","year":"2016","journal-title":"J\u00a0Gen Virol"},{"key":"10.1053\/j.gastro.2022.10.008_bib124","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hep.28685","article-title":"Lack of immunological DNA sensing in hepatocytes facilitates hepatitis B virus infection","volume":"64","author":"Thomsen","year":"2016","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.10.008_bib125","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","article-title":"Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B","volume":"138","author":"Fisicaro","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.10.008_bib126","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.10.008_bib127","first-page":"19","article-title":"A\u00a0phase IIa trial of subcutaneously administered PD-L1 antibody ASC22 (envafolimab) in patients with chronic hepatitis B","volume":"74","author":"Wang","year":"2021","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.10.008_bib128","first-page":"54","article-title":"Liver directed targeting of PD-L1 with R07191863, a locked nucleic acid, in chronic hepatitis B: first report of phase 1 tolerability, pharmacokinetics, and pharmacodynamics","volume":"74","author":"Geretti","year":"2021","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.10.008_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2021.101285","article-title":"TCR gene-engineered cell therapy for solid tumors","volume":"34","author":"Tan","year":"2021","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1053\/j.gastro.2022.10.008_bib130","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"'Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1053\/j.gastro.2022.10.008_bib131","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/hep.510250631","article-title":"Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer","volume":"25","author":"Lau","year":"1997","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.10.008_bib132","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jcyt.2018.02.002","article-title":"HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice","volume":"20","author":"Kruse","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1053\/j.gastro.2022.10.008_bib133","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jhep.2010.10.025","article-title":"Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines","volume":"55","author":"Gehring","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.10.008_bib134","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/hep.31503","article-title":"Immune-mobilizing monoclonal T cell receptors mediate specific and rapid elimination of hepatitis B-infected cells","volume":"72","author":"Fergusson","year":"2020","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.10.008_bib135","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2014.10.001","article-title":"Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient","volume":"62","author":"Qasim","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.10.008_bib136","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1007\/s12072-021-10250-2","article-title":"Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial","volume":"15","author":"Meng","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1053\/j.gastro.2022.10.008_bib137","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/21645515.2019.1651141","article-title":"Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial","volume":"16","author":"Zoulim","year":"2020","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1053\/j.gastro.2022.10.008_bib138","article-title":"The design and development of a multi-HBV antigen encoded in chimpanzee adenoviral and modified vaccinia ankara viral vectors; a novel therapeutic vaccine strategy against HBV","volume":"8","author":"Chinnakannan","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1053\/j.gastro.2022.10.008_bib139","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1053\/j.gastro.2020.01.032","article-title":"Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice","volume":"158","author":"Michler","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1053\/j.gastro.2022.10.008_bib140","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/vaccines10010045","article-title":"The safety and efficacy of a therapeutic vaccine for chronic hepatitis B: a follow-up study of phase III clinical trial","volume":"10","author":"Akbar","year":"2022","journal-title":"Vaccines"},{"issue":"6","key":"10.1053\/j.gastro.2022.10.008_bib141","article-title":"Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib\/IIa study","volume":"3","author":"Ma","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1053\/j.gastro.2022.10.008_bib142","first-page":"17","article-title":"Efficacy and safety of the siRNA JNJ-3989 and\/or the capsid assembly modulator JNJ-6379 for the treatment of chronic hepatitis B virus infection: results from the phase 2b REEF-1 study","volume":"74","author":"Yuen","year":"2021","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.10.008_bib143","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.10.008_bib144","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/hep.21896","article-title":"Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans","volume":"46","author":"Schulze","year":"2007","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.10.008_bib145","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"10.1053\/j.gastro.2022.10.008_bib146","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/ajg.2009.248","article-title":"Histological disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels","volume":"104","author":"Nguyen","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.10.008_bib147","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2014.01.044","article-title":"Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA","volume":"146","author":"Chan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.10.008_bib148","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/hep.30417","article-title":"Entecavir and peginterferon alfa-2a in adults with hepatitis b e antigen-positive immune-tolerant chronic hepatitis B virus infection","volume":"69","author":"Feld","year":"2019","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.10.008_bib149","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1097\/MCG.0b013e3182a9a2e1","article-title":"Predictors of significant fibrosis in chronic hepatitis B patients with low viremia","volume":"48","author":"Abdo","year":"2014","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1053\/j.gastro.2022.10.008_bib150","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.29213","article-title":"A\u00a0potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha","volume":"66","author":"Cao","year":"2017","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.10.008_bib151","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1053\/j.gastro.2010.01.042","article-title":"Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death","volume":"138","author":"Chen","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.10.008_bib152","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.cgh.2021.01.019","article-title":"Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase","volume":"20","author":"Huang","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.10.008_bib153","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-230X-12-14","article-title":"Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis","volume":"12","author":"Jin","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"10.1053\/j.gastro.2022.10.008_bib154","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/hep.27382","article-title":"Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis","volume":"61","author":"Xiao","year":"2015","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.10.008_bib155","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1080\/17474124.2021.1880894","article-title":"Comparison of two-dimensional shear wave elastography, magnetic resonance elastography, and three serum markers for diagnosing fibrosis in patients with chronic hepatitis B: a meta-analysis","volume":"15","author":"Dong","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.10.008_bib156","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.3748\/wjg.v16.i38.4832","article-title":"Liver stiffness measurements in patients with HBV vs HCV chronic hepatitis: a comparative study","volume":"16","author":"Sporea","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.10.008_bib157","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S2468-1253(19)30087-1","article-title":"Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study","volume":"4","author":"Sonneveld","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508522011660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508522011660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T15:38:24Z","timestamp":1758037104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508522011660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":156,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0016508522011660"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2022.10.008","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Best Practice in Hepatitis B Management and Understanding Long-term Prospects for Cure","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2022.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}